.jpg)
Modern oncology faces a crucial challenge: how to extract quantitative and biologically relevant information from medical images to characterize tumors non-invasively. Traditionally, conventional radiomics analyzes the entire tumor mass, but its interpretative capacity is limited. Recent advances in artificial intelligence propose unified frameworks that integrate deep segmentation, explainable classification, and radiomic analysis to discover reproducible imaging signatures. These systems combine robust segmentation models (such as U-Net or variants) with visual attention mechanisms (Grad-CAM) that identify diagnostically relevant regions. Through adaptive strategies based on mutual information, patient-specific signatures are extracted, which are validated by downstream deep learning models. Additionally, radiomic features from those regions are evaluated with classical models and interpreted with SHAP, revealing discriminative biomarkers. This approach outperforms global radiomics by offering greater discriminative performance and, above all, biological interpretability that physicians can audit. Applied to public breast, kidney, and brain datasets, as well as private clinical cohorts, it demonstrates its potential for non-invasive tumor characterization.
For these solutions to reach the real clinical environment, a robust technological ecosystem is required. This is where the expertise of Q2BSTUDIO comes into play, a company specialized in AI for businesses that develops custom applications capable of integrating interpretable deep learning models into hospital workflows. The practical implementation of these frameworks requires custom software to manage everything from image acquisition to the visualization of radiomic signatures, including AWS and Azure cloud services that ensure scalability and regulatory compliance. Furthermore, the security of healthcare data is critical; therefore, Q2BSTUDIO offers cybersecurity and pentesting to protect cloud infrastructures. Integration with hospital information systems is enhanced through AI agents that automate segmentation and reporting processes, while business intelligence services and Power BI convert radiomic results into accessible dashboards for medical teams. All of this materializes in custom applications that translate computational research into clinical practice, enabling truly interpretable and reproducible precision oncology.
